ArticleWorld journal of urology2015
TOOKAD® Soluble focal therapy: pooled analysis of three phase II studies assessing the minimally invasive ablation of localized prostate cancer.
Article in World journal of urology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 2 syntheses or guidelines pooled it, 96 citations in OpenAlex.
- Oncological results and cancer control definition in focal therapy for Prostate Cancer: a systematic review.Prostate cancer and prostatic diseases · 2024Pooled it
- Erectile function after focal therapy for localized prostate cancer: a systematic review.International journal of impotence research · 2021Pooled it
- Randomized Trial of Partial Gland Ablation with Vascular Targeted Phototherapy versus Active Surveillance for Low Risk Prostate Cancer: Extended Followup and Analyses of Effectiveness.The Journal of urology · 2018Trial
- Vascular targeted photodynamic therapy with TOOKAD® Soluble (WST11) in localized prostate cancer: efficiency of automatic pre-treatment planning.Lasers in medical science · 2017Trial
- Recent Advances in Two-Photon-Activatable Metal Complexes for Photodynamic Therapy.Angewandte Chemie (International ed. in English) · 2026Review
- The Safety and Efficacy of Vascular-Targeted Photodynamic Therapy in Low-Risk Prostate Cancer.Cancers · 2025Article
- Proteomics Reveals Mechanisms of Delayed Keratoconus Progression: A Study of Corneas Following Two Light-Activated Crosslinking Treatments.Investigative ophthalmology & visual science · 2025Article
- Advantages of Long-Wavelength PhotosensitizerPharmaceuticals (Basel, Switzerland) · 2023Article
- A Canadian center's experience on whole-gland salvage therapy for radio-recurrent prostate cancer with various modalities.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2023Review
- Emerging photodynamic/sonodynamic therapies for urological cancers: progress and challenges.Journal of nanobiotechnology · 2022Review
- Bioactivity and Development of Small Non-Platinum Metal-Based Chemotherapeutics.Pharmaceutics · 2022Review
- Photoactive and Luminescent Transition Metal Complexes as Anticancer Agents: A Guiding Light in the Search for New and Improved Cancer Treatments.Biomedicines · 2022Review
- Subcutaneous Xenograft Models for Studying PDT In Vivo.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Photodynamic therapy for prostate cancer: Recent advances, challenges and opportunities.Frontiers in oncology · 2022Review
- How to improve photodynamic therapy-induced antitumor immunity for cancer treatment?Theranostics · 2022Review
- Tumour irradiation combined with vascular-targeted photodynamic therapy enhances antitumour effects in pre-clinical prostate cancer.British journal of cancer · 2021Article
- Focal therapy for primary and salvage prostate cancer treatment: a narrative review.Translational andrology and urology · 2021Review
- Positron Emission Tomography/Computed Tomography with Gallium-68-labeled Prostate-specific Membrane Antigen Detects Relapse After Vascular-targeted Photodynamic Therapy in a Prostate Cancer Model.European urology focus · 2021Article
- Photodynamic diagnosis and therapy for urothelial carcinoma and prostate cancer: new imaging technology and therapy.International journal of clinical oncology · 2021Review
- Critical discussion of the applications of metal complexes for 2-photon photodynamic therapy.Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 8 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the 6-month effects of the recommended drug and light dosage in focal vascular-targeted photodynamic therapy (VTP) using TOOKAD(®) Soluble in patients with localized prostate cancer (LPCa).
methodsWe performed a pooled analysis of 117 men with LPCa, PSA <10 ng/mL, and Gleason score ≤ 7 (3 + 4), from 3 studies who received a 10-min intravenous infusion of a single dose of 4 mg/kg TOOKAD(®) Soluble, activated by a 753-nm light at 200 J/cm delivered in the prostate by transperineal fibres under transrectal ultrasound guidance. Primary endpoint was 6-month negative biopsies in the treated lobe(s). PSA was measured at month 1, 3, and 6. Magnetic resonance imaging was performed at day 7, month 3, and 6. International Prostate Symptom Score (IPSS), International Index of Erectile Function (IIEF-5) and adverse events were reported at day 7, month 1, 3, and 6.
resultsMonth 6 negative biopsy rate was 68.4 % in the overall evaluable population (N = 114) and 80.6 % for patients treated by hemiablation with light density index (LDI) ≥ 1 (N = 67). Mean prostate necroses at week-1 were 76.5 and 86.3 %, respectively. In both groups, PSA levels at month 6 decreased by 2.0 ng/mL. Small changes from baseline for IPSS and IIEF-5 indicated a slight improvement in urinary function and a slight deterioration in sexual function.
conclusionsFocal VTP treatment with TOOKAD(®) Soluble at 4 mg/kg and 200 J/cm resulted in a negative 6-month biopsy rate of 68.4 % for the whole population and 80.6 % for patients treated by hemiablation with LDI ≥ 1. The treatment was well tolerated. Two phase III studies will reach completion in early 2015.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.